Skip to main content

Replimune Group Inc (REPL) Stock

Replimune Group Inc Stock Details, Movements and Public Alerts

Stock Details

Replimune Group Inc (REPL), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $5.22. Over the past 52 weeks, it has ranged between $1.50 and $13.24. This places the current price at 39.4% of its 52-week high and 248.0% above its 52-week low. Recent trading volume was recorded at 4,546,606. The 14-day Relative Strength Index (RSI) stands at 60.44, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $5.14 by 1.56%. Similarly, it is below its 200-day moving average of $6.82 by 23.46%. The MACD histogram is 0.44, indicating bullish momentum (MACD Line: 0.03, Signal Line: -0.41). There are currently 2 active alerts set for REPL by users.

52-Week Range

$13.24 - $1.50

-60.57% from high · +248.00% from low

Avg Daily Volume

8,362,320

20-day average

100-day avg: 4,113,519

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

1.60

EV/EBITDA

-0.24

EPS (TTM)

-$3.44

Beta

0.12

Less volatile than market

Q:How is REPL valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is REPL's risk profile compared to the market?
With a beta of 0.12, Replimune Group Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.60 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-318,880,992

Return on Equity

-90.90%

Return on Assets

-43.20%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is REPL's business model?
Profitability metrics are not available for this stock.
Q:What are REPL's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$431.0M

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

82.57M

Book Value/Share

$2.64

Asset Type

Common Stock

Q:What is REPL's market capitalization and position?
Replimune Group Inc has a market capitalization of $431.0M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 82.57M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does REPL's price compare to its book value?
Replimune Group Inc's book value per share is $2.64, while the current stock price is $5.22, resulting in a price-to-book (P/B) ratio of 1.97. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$3.50

32.95% downside potential

Analyst Recommendations

Strong Buy

1

Buy

5

Hold

2

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for REPL?
8 analysts cover REPL with 75% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $3.50 implies -33.0% downside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on REPL?
Current analyst recommendations:1 Strong Buy, 5 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: May 17, 2026, 02:00 AM

Technical Indicators

RSI (14-day)

60.44

Neutral

50-Day Moving Average

$5.14

1.56% above MA-50

200-Day Moving Average

$6.82

-23.46% below MA-200

MACD Line

0.03

MACD Signal

-0.41

MACD Histogram

0.44

Bullish

Q:What does REPL's RSI value tell investors?
The RSI (Relative Strength Index) for REPL is currently 60.44, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret REPL's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.03 above the signal line at -0.41, with histogram at 0.44. This bullish crossover suggests upward momentum is building. The 50-day MA ($5.14) is below the 200-day MA ($6.82), forming a death cross pattern that often warns of extended weakness. Price is currently between the MAs, suggesting transition.

Indicators last updated: May 17, 2026, 12:31 AM

Active Alerts

Alert Condition
Reaches new 52-week low
Threshold
N/A
Created
May 13, 2026, 07:13 AM
Alert Condition
Reaches new 52-week high
Threshold
N/A
Created
May 13, 2026, 07:13 AM

Stay Ahead of the Market with Replimune Group Inc Alerts

Set up price alerts for Replimune Group Inc and get notified instantly when the price hits your target. Never miss an important price movement again.